Code Biotherapeutics

Pioneering targeted delivery of precision genetic medicines

Founded 2020

United States 23 employees Series A Total: $85.00M Biotechnology, Health Care +1

Code Biotherapeutics is a trailblazer in the field of genetic medicine, dedicated to the development of precision therapies for individuals affected by genetic disorders. Founded in 2020, this United States-based company operates at the intersection of Biotechnology, Health Care, and Life Sciences.

The driving force of Code Biotherapeutics is its proprietary 3DNA® platform. This innovative, multivalent, synthetic DNA delivery technology is engineered to circumvent the traditional challenges associated with genetic medicine delivery, such as dose-related toxicity, off-target effects, and vector manufacturing complexity. It also boasts improved bioavailability and the unique ability to re-dose.

The company's internal pipeline focuses on diseases like Duchenne’s Muscular Dystrophy (DMD) and extends research to organs such as the lungs, pancreas, and liver. In a significant show of confidence, Code Biotherapeutics secured a $75.00M Series A investment in June 2022 from prominent investors, including 4BIO Capital, Amgen Ventures, and Takeda Ventures.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$75.00M	7	4BIO Capital, Amgen Ventures +5	01 Jun 2022
Seed	$10.00M	6	4BIO Capital, CureDuchenne Ventures +4	01 Apr 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$75.00M

4BIO Capital, Amgen Ventures +5

01 Jun 2022

Seed

$10.00M

4BIO Capital, CureDuchenne Ventures +4

01 Apr 2021

FAQ About Code Biotherapeutics

Pioneering targeted delivery of precision genetic medicines

Code Biotherapeutics was founded in 2020.

Code Biotherapeutics is headquartered in United States.

Code Biotherapeutics operates in Biotechnology, Health Care and Life Sciences. Its work centres on precision genetic medicines, gene therapy, genetic diseases and non-viral delivery. Its customers include Healthcare providers, Patients with life-threatening diseases and Biopharma partners.

Code Biotherapeutics has a B2B, B2D and Platform business model. Its revenue comes from Licensing and Service Fee.

Code Biotherapeutics has approximately 23 employees.

Code Biotherapeutics has completed 2 funding rounds, raising a total of $85.00M. The latest funding stage is Series A.

Code Biotherapeutics offers: Development of genetic medicines, Non-viral DNA delivery technology, Research in rare diseases.

Top alternatives and competitors to Code Biotherapeutics include Gennao Bio, Solid Biosciences, Dyne Therapeutics, MeiraGTx, Affinia Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Code Biotherapeutics and Gennao Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Code Biotherapeutics

Services & Products

Target Customers

Funding Rounds & Investors (2)

Code Biotherapeutics Alternatives & Competitors

FAQ About Code Biotherapeutics